Bristol Myers invests $35M into Immatics; FibroGen names new CEO
Bristol Myers Squib has made a $35 million investment into the T cell-focused biotech Immatics, purchasing over 2.4 million shares.
The move will allow for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
